We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Diabetes & Endocrinology

Diabetes & Endocrinology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Optimizing Diabetes Management in Cirrhosis: A Practical Clinical Guide
Diabetes & Endocrinologycirrhosisdiabetes

Optimizing Diabetes Management in Cirrhosis: A Practical Clinical Guide

By MedXY|Aug 18, 2026

Cirrhosis entwined with diabetes presents unique clinical challenges. This article offers a pragmatic framework for diagnosis, tailored therapies, and multidisciplinary care to enhance outcomes across liver disease stages.

Comparative Performance of Four AI Systems for Detecting Referable Diabetic Retinopathy in Tanzania: A Real-World Evaluation
AIlow-resource settingsretinopathy đái tháo đường

Comparative Performance of Four AI Systems for Detecting Referable Diabetic Retinopathy in Tanzania: A Real-World Evaluation

By MedXY|Aug 12, 2026

This study evaluates four commercially available AI systems for diabetic retinopathy screening in Tanzania, demonstrating high sensitivity for referable and proliferative DR and highlighting considerations for implementation in low-resource

Liver, Portal, and Systemic Thyroid Hormone Alterations in End-Stage MASH: Distinct Diagnostic and Prognostic Roles for T3/rT3 Ratio and T4
Clinical Updatesthyroid hormone metabolismResmetirom

Liver, Portal, and Systemic Thyroid Hormone Alterations in End-Stage MASH: Distinct Diagnostic and Prognostic Roles for T3/rT3 Ratio and T4

By MedXY|Aug 11, 2026

End-stage metabolic dysfunction-associated steatohepatitis (MASH) features profound disruptions in thyroid hormone metabolism across liver, portal, and systemic compartments, with the hepatic T3 level and systemic T3/rT3 ratio serving as se

Low Faecal Elastase in Type 1 Diabetes: Implications of Exocrine Pancreatic Insufficiency Linked to Disease Duration
Diabetes & EndocrinologyExocrine Pancreatic InsufficiencyDiabetes Duration

Low Faecal Elastase in Type 1 Diabetes: Implications of Exocrine Pancreatic Insufficiency Linked to Disease Duration

By MedXY|Aug 11, 2026

A significant subset of type 1 diabetes patients exhibit low faecal elastase indicative of exocrine pancreatic insufficiency (EPI), associated with longer diabetes duration but not with major changes in diet or symptoms, highlighting the ne

Temple Syndrome: Unveiling a Hidden Multi-System Growth Disorder and Introducing a New Diagnostic Score
Diabetes & Endocrinologyclinical scoring systemendocrine phenotype

Temple Syndrome: Unveiling a Hidden Multi-System Growth Disorder and Introducing a New Diagnostic Score

By MedXY|Aug 11, 2026

Temple syndrome is an under-recognised imprinting disorder with complex endocrine and growth abnormalities. This large-cohort study clarifies its phenotype, highlights growth hormone therapy benefits, and proposes a novel clinical scoring s

Impact of Residual C-Peptide on Long-Term Outcomes in Type 1 Diabetes: Insights from the Scottish Cohort
Diabetes & Endocrinologydiabetic complicationstype 1 diabetes

Impact of Residual C-Peptide on Long-Term Outcomes in Type 1 Diabetes: Insights from the Scottish Cohort

By MedXY|Aug 11, 2026

This study highlights that higher baseline and maintained C-peptide levels in type 1 diabetes are linked to reduced risks of acute complications and retinopathy, underscoring the importance of preserving endogenous insulin secretion.

Efficacy and Safety of Once-Weekly Semaglutide 2.4 mg in Chinese Adults with Overweight or Obesity: Insights from the STEP 12 Trial and Regional Evidence
Clinical Updatesweight managementsemaglutide

Efficacy and Safety of Once-Weekly Semaglutide 2.4 mg in Chinese Adults with Overweight or Obesity: Insights from the STEP 12 Trial and Regional Evidence

By MedXY|Aug 11, 2026

This review synthesizes evidence from the STEP 12 trial and related studies demonstrating that once-weekly semaglutide 2.4 mg significantly reduces bodyweight and improves cardiometabolic outcomes in Chinese adults with overweight or obesit

GLP-1 Receptor Agonists May Reduce Hospital Admissions for Alcohol and Substance Use Disorders: Insights from a Swedish Nationwide Study
Diabetes & Endocrinologyhospitalisation ratesdiabetes

GLP-1 Receptor Agonists May Reduce Hospital Admissions for Alcohol and Substance Use Disorders: Insights from a Swedish Nationwide Study

By MedXY|Aug 10, 2026

This Swedish register-based study reveals that GLP-1 receptor agonists are associated with significantly reduced hospitalisations for alcohol and substance use disorders during treatment, with some lasting benefits after discontinuation of

Crowded Optic Discs and Risk Stratification of NAION in GLP-1 Receptor Agonist Users: Insights from a Large Multicenter Study
Diabetes & Endocrinologycup-to-disc ratioNAION

Crowded Optic Discs and Risk Stratification of NAION in GLP-1 Receptor Agonist Users: Insights from a Large Multicenter Study

By MedXY|Aug 10, 2026

This large multicenter study reveals that nonarteritic anterior ischemic optic neuropathy (NAION) patients exposed to GLP-1 receptor agonists exhibit similar optic disc crowding compared to nonexposed patients, with smaller cup-to-disc rati

Balancing Benefits and Risks: Prophylactic Thyroidectomy Outcomes in Pediatric MEN2 Patients
Diabetes & EndocrinologyMEN2prophylactic thyroidectomy

Balancing Benefits and Risks: Prophylactic Thyroidectomy Outcomes in Pediatric MEN2 Patients

By MedXY|Aug 9, 2026

Prophylactic thyroidectomy in children with MEN2 mutations shows excellent short-term cancer control but carries notable risk of permanent hypoparathyroidism, especially under age 5, highlighting the need for expert multidisciplinary surgic

Pooled Analysis of SELECT, FLOW, and SOUL Links Semaglutide to Reduced Kidney Outcomes
Diabetes & Endocrinologycardio-kidney-metabolic diseasesemaglutide

Pooled Analysis of SELECT, FLOW, and SOUL Links Semaglutide to Reduced Kidney Outcomes

By MedXY|Aug 8, 2026

A prespecified pooled analysis of three phase 3 trials including 30,787 participants found semaglutide reduced major kidney outcomes versus placebo, with a 16% relative risk reduction in the primary composite and a favourable safety profile across cardio-kidney-metabolic disease.

Linking Endometriosis Subtypes to Increased Risk of Type 2 Diabetes: Insights from the ARCHES Study
Diabetes & Endocrinologyendometriosiswomen's health

Linking Endometriosis Subtypes to Increased Risk of Type 2 Diabetes: Insights from the ARCHES Study

By MedXY|Aug 18, 2026

The ARCHES retrospective cohort study reveals that endometriosis significantly elevates the risk of type 2 diabetes, particularly in specific subtypes and among premenopausal women with lower BMI, highlighting the importance of subtype-spec

Ersodetug for Refractory Hypoglycemia Due to Malignant Insulin-Secreting Tumors: A Compassionate Use Case Series
Diabetes & Endocrinologyhyperinsulinisminsulin receptor antibody

Ersodetug for Refractory Hypoglycemia Due to Malignant Insulin-Secreting Tumors: A Compassionate Use Case Series

By MedXY|Aug 8, 2026

This case series describes compassionate use of ersodetug in eight adults with refractory hypoglycemia from malignant insulin-secreting tumors, demonstrating improved glycemic control, reduced hypoglycemia, and enhanced functional status.

Early Identification and Monitoring of At-Risk Children Significantly Improves Outcomes in Type 1 Diabetes
Diabetes & Endocrinologydisease managementtype 1 diabetes

Early Identification and Monitoring of At-Risk Children Significantly Improves Outcomes in Type 1 Diabetes

By MedXY|Aug 8, 2026

Population-based genetic screening and prospective follow-up of at-risk children reduce the severity of type 1 diabetes at diagnosis and enhance one-year treatment outcomes, including lower HbA1c and insulin requirements.

Systemic Interleukin-6 Inhibition as a Novel Approach to Reduce Diabetic Retinopathy Risk and Progression
Diabetes & EndocrinologyInterleukin-6Bệnh lý võng mạc

Systemic Interleukin-6 Inhibition as a Novel Approach to Reduce Diabetic Retinopathy Risk and Progression

By MedXY|Aug 6, 2026

Systemic IL-6 inhibitors are linked to significantly reduced risks of diabetic retinopathy development, progression, and vision-threatening complications, suggesting therapeutic potential for diabetic eye disease.

Impact of Maternal Third-Trimester TRAb Levels on Neonatal Thyroid Function and Early Childhood Neurodevelopment: Insights from a Bidirectional Cohort Study
Diabetes & EndocrinologyGraves' Diseasecohort study

Impact of Maternal Third-Trimester TRAb Levels on Neonatal Thyroid Function and Early Childhood Neurodevelopment: Insights from a Bidirectional Cohort Study

By MedXY|Aug 5, 2026

Elevated maternal third-trimester TRAb levels in Graves’ disease are linked to neonatal thyroid dysfunction and impaired neurodevelopment at 24 months, independent of neonatal thyroid status, highlighting the need for prenatal monitor

Leveraging Polygenic Scores to Predict Diabetes Risk After Gestational Diabetes: Insights from a 30-Year Cohort Study
Diabetes & Endocrinologytype 1 diabetesPolygenic Scores

Leveraging Polygenic Scores to Predict Diabetes Risk After Gestational Diabetes: Insights from a 30-Year Cohort Study

By MedXY|Aug 18, 2026

Polygenic scores can predict type 1 diabetes risk after gestational diabetes, especially when combined with clinical factors, but show limited utility for type 2 diabetes prediction.

Distinguishing Partial Lipodystrophy from Cushing’s Syndrome: Clinical Overlaps and Diagnostic Challenges
Diabetes & EndocrinologyCushing's SyndromeClinical Risk Scores

Distinguishing Partial Lipodystrophy from Cushing’s Syndrome: Clinical Overlaps and Diagnostic Challenges

By MedXY|Aug 5, 2026

Partial lipodystrophy (PLD) often mimics Cushing’s syndrome (CS), complicating diagnosis. This study reveals overlapping features, limitations of CS clinical scores in PLD, and underscores the need for careful differential diagnosis t

Prior Authorization Suspension Boosts Access to Diabetes Technology and Improves Glycemic Control in Underserved Populations
Diabetes & Endocrinologyprior authorizationhealth equity

Prior Authorization Suspension Boosts Access to Diabetes Technology and Improves Glycemic Control in Underserved Populations

By MedXY|Aug 5, 2026

Suspension of prior authorization requirements led to increased access to CGM and insulin pumps and significant HbA1c improvement in type 1 diabetes patients in a safety net clinic, highlighting benefits of reducing administrative barriers.

Structured Telehealth Community Health Worker-Clinician Feedback and Diabetes Outcomes: A Randomized Clinical Trial
Diabetes & Endocrinologytelehealthdiabetes

Structured Telehealth Community Health Worker-Clinician Feedback and Diabetes Outcomes: A Randomized Clinical Trial

By MedXY|Aug 5, 2026

This study demonstrates that a telehealth-supported community health worker program with structured feedback loops significantly improves diabetes control and care adherence in low-income Hispanic adults.

Prev
8 / 25
1…678910…25
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

Browse by specialty

Open language-specific specialty feeds and department pages.

news6629 articlesCardiology1375 articlesClinical Updates1288 articlesOncology1139 articlesDiabetes & Endocrinology842 articlesNeurology820 articlesPublic Health595 articlesGastroenterology572 articles
Hematology-Oncology
487 articles
Pediatrics484 articles
Internal Medicine444 articles